Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial by Steve, Bain
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
Diabetes Care
                               
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa43485
_____________________________________________________________
 
Paper:
Mathieu, C., Dandona, P., Gillard, P., Senior, P., Hasslacher, C., Araki, E., Lind, M., Bain, S., Jabbour, S.,  et. al.
(2018).  Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2
Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care, 41(9), 1938-1946.
http://dx.doi.org/10.2337/dc18-0623
 
 
 
 
 
 
 
_____________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
http://www.swansea.ac.uk/library/researchsupport/ris-support/ 
 1 
 
Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 
Diabetes (The DEPICT-2 study): 24-Week Results from a Randomized  
Controlled Trial 
Short running title (>47 characters and spaces combined): DEPICT-2: Dapagliflozin in 
type 1 diabetes  
    
Chantal Mathieu1, MD; Paresh Dandona2, MD; Pieter Gillard1, MD; Peter Senior3, 
MBBS, PhD; Christoph Hasslacher4, MD; Eiichi Araki5, MD, PhD; Marcus Lind6,7, MD, 
PhD; Stephen C Bain8, FRCP; Serge Jabbour9, MD; Niki Arya10, MS; Lars Hansen11*, 
MD, PhD; Fredrik Thorén12,MD; Anna Maria Langkilde12, MD; on behalf of the DEPICT-
2 Investigators* 
 
1Clinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium; 
2Department of Medicine, State University of New York at Buffalo, Buffalo, NY, USA; 
3Division of Endocrinology, University of Alberta, Edmonton, Canada; 4Diabetesinstitut 
Heidelberg, Heidelberg, Germany; 5Department of Metabolic Medicine, Faculty of Life 
Sciences, Kumamoto University, Kumamoto, Japan; 6Institute of Medicine, University of 
Gothenburg, Gothenburg, Sweden; 7Department of Medicine, NU-Hospital Group, 
Uddevalla, Sweden; 8Diabetes Research Unit, Swansea University, Wales, United 
Kingdom; 9Department of Endocrinology, Diabetes and Metabolic Disease, Sidney 
Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, 
USA; 10AstraZeneca, Gaithersburg, MD, USA; 11MedImmune, Gaithersburg, MD, USA; 
12AstraZeneca, Gothenburg, Sweden.  
2 
 
*At the time of the study, LH worked at Bristol-Myers Squibb, Princeton, NJ, USA 
 
Corresponding author: Chantal Mathieu  
Address: Clinical and Experimental Endocrinology, University of Leuven, Leuven, 
Belgium 
Email: chantal.mathieu@uzleuven.be  
Telephone number: 003216346994 
Fax number: 003216346989 
 
Word count: 4342 
Number of Tables: 2  
Number of Figures: 2  
 
 
  
3 
 
Abstract 
Objective: This 24-week, double-blinded, phase 3 clinical trial (DEPICT-2; 
NCT02460978) evaluated efficacy and safety of dapagliflozin as adjunct therapy to 
adjustable insulin in patients with inadequately controlled type 1 diabetes (HbA1c 7.5–
10.5%).  
Methods: Patients were randomized 1:1:1 to dapagliflozin 5 mg (n=271), 10 mg 
(n=270), or placebo (n=272) plus insulin. Insulin dose was adjusted by investigators 
according to self-monitored glucose readings, local guidance, and individual 
circumstances.  
Results: Baseline characteristics were balanced between treatment groups. At Week 
24, dapagliflozin significantly decreased HbA1c (primary outcome; difference versus 
placebo [95% CI]: dapagliflozin 5 mg, −0.37% [−0.49, −0.26]; dapagliflozin 10 mg, –
0.42% [−0.53, −0.30]), total daily insulin dose (−10.78% [−13.73, −7.72], −11.08% 
[−14.04, −8.02], respectively), and body weight (−3.21% [−3.96, −2.45], −3.74% [−4.49, 
−2.99], respectively); p<0.0001 for all. Mean interstitial glucose, amplitude of glucose 
excursion and percent of readings within target glycemic range (>70–≤180 mg/dL) 
versus placebo were significantly improved. More patients receiving dapagliflozin 
achieved a reduction in HbA1c ≥0.5% without severe hypoglycemia compared with 
placebo. Adverse events were reported for 72.7%, 67.0%, and 63.2% of patients 
receiving dapagliflozin 5 mg, 10 mg and placebo, respectively. Hypoglycemia, including 
severe hypoglycemia, was balanced between groups. There were more adjudicated 
definite diabetic ketoacidosis (DKA) events with dapagliflozin; 2.6%, 2.2%, and 0% for 
dapagliflozin 5 mg, 10 mg and placebo, respectively.  
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Conclusion: Dapagliflozin as adjunct therapy to adjustable insulin in patients with type 
1 diabetes was well tolerated, and improved glycemic control with no increase in 
hypoglycemia versus placebo but with more DKA events. 
 
Current word count: 249 (maximum 250 words) 
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Introduction  
Less than one third of patients with type 1 diabetes achieve optimal glycemic control 
(HbA1c <7% [<53 mmol/mol]) (1, 2). Even when target HbA1c levels are achieved, 
there is still evidence for excess mortality in patients with type 1 diabetes (3). Insulin 
therapy is the mainstay of treatment (4); however, it is associated with hypoglycemia (5-
7) and weight gain (8), both of which are important cardiovascular risk factors (9, 10). 
Occurrence of hypoglycemia hinders the achievement of glycemic targets and affects 
the quality of life of patients (11-13), and severe hypoglycemia is a potentially serious 
event. Other challenges for patients with type 1 diabetes include excessive glycemic 
variability and hypoglycemia unawareness (11). Thus, strategies to improve glycemic 
control, without increasing hypoglycemia or weight gain would fulfill an unmet need. 
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are insulin-independent, glucose-
dependent antihyperglycemic agents that have demonstrated potential for use as 
adjunct therapy to insulin in the treatment of type 1 diabetes, providing additional 
treatment benefits such as weight loss and decreased glycemic variability. 
Dapagliflozin, an SGLT2 inhibitor approved for the treatment of type 2 diabetes, and 
sotagliflozin, a nonselective SGLT2/SGLT1 inhibitor, have shown promise as adjunct 
treatments for type 1 diabetes in previous studies (14-17). The recent, randomized, 
placebo-controlled, phase 3, 24-week DEPICT-1 study demonstrated that when used as 
adjunct therapy to adjustable insulin in patients with inadequately controlled type 1 
diabetes, dapagliflozin significantly decreased HbA1c, body weight, total insulin dose, 
and glycemic variability. Treatment was generally well tolerated, with similar levels of 
hypoglycemia compared with placebo (16). The overall adverse event (AE) profile was 
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consistent with that observed in patients with type 2 diabetes. There were few events of 
diabetic ketoacidosis (DKA), and these were manageable with standard care.  
Similar to the DEPICT-1 study, the current 24-week DEPICT-2 study investigated the 
efficacy and safety of dapagliflozin as adjunct therapy to adjustable insulin, providing 
further supportive evidence for its use in the treatment of type 1 diabetes.  
 
Materials and methods   
Study design 
DEPICT-2 was the second of two, randomized, double-blind, parallel-controlled, three-
arm, multicenter, phase 3 studies evaluating the efficacy and safety of dapagliflozin 5 
mg and 10 mg as adjunct therapy to adjustable insulin in adult patients with type 1 
diabetes and inadequate glycemic control. The methodology has been published 
previously (16). The study was conducted at 136 sites in the following countries: 
Argentina, Belgium, Canada, Chile, Germany, Japan, the Netherlands, Poland, the 
Russian Federation, Sweden, Switzerland, the United Kingdom, and the United States, 
in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines as 
defined by the International Conference on Harmonization. It was approved by the 
institutional review boards and independent ethics committees for all participating 
centers. All participants provided written informed consent. For ≥18–<20-year-old 
patients from Japan, informed consent was obtained from their parents/guardians. The 
DEPICT-2 study is registered on ClinicalTrials.gov (NCT02460978).  
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Study participants 
This study included adult patients with inadequately controlled type 1 diabetes (HbA1c, 
7.7–11.0% [61–97 mmol/mol] at screening/enrolment; 7.5–10.5% [58–91 mmol/mol] at 
randomization) receiving adjustable insulin via multiple daily injections (MDI) or 
continuous subcutaneous insulin infusion (CSII) for ≥12 months prior to screening (total 
insulin dose ≥0.3 IU/kg/day for ≥3 months prior to screening), and with C-peptide <0.7 
ng/mL and BMI ≥18.5 kg/m2. Patients were excluded if they had type 2 diabetes, or a 
history of pancreatic surgery, chronic pancreatitis or other pancreatic disorders resulting 
in decreased β-cell capacity, signs of poorly controlled diabetes (including DKA 
requiring medical intervention or hospitalization for hyperglycemia or hypoglycemia 
within 1 month prior to screening), cardiovascular disease (within 6 months prior to 
screening), unstable/rapidly-progressing renal disease, significant hepatic disease, 
malignancy (within 5 years) or had previously used any SGLT2 inhibitor. A 
comprehensive list of inclusion and exclusion criteria is provided in Supplementary 
table 1.  
 
Study medications and procedures 
Eligible patients entered an 8-week lead-in period to optimize diabetes management. 
On completing the lead-in period, patients with an HbA1c of 7.5–10.5% (58–91 
mmol/mol) were randomized 1:1:1 using an interactive voice/web response system to 
oral dapagliflozin 5 mg, 10 mg, or placebo once daily. Patients were stratified by use of 
continuous glucose monitoring (CGM) at baseline (in which case they would continue to 
use their own device during the study in addition to the masked study CGM), use of 
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CSII or MDI for insulin administration at baseline, and baseline HbA1c (7.5–<9.0% [58–
<75 mmol/mol] or 9.0–10.5% [75–91 mmol/mol]). The lead-in period was followed by a 
24-week, short-term, double-blind treatment period; a 28-week, long-term subject- and 
site-blinded extension phase assessing safety; followed by a 4-week follow-up period; 
the 24-week results are reported here. 
Glycemic control (including self-monitoring of blood glucose [SMBG]) and home ketone 
(Beta-hydroxybutyrate [BOHB]) measurements were assessed at each study visit. 
Insulin doses were adjusted as deemed appropriate by the investigator, based on 
SMBG readings (recommended 4 times/day at a minimum and 6 times/day during 
protocol specified periods of intense glucose monitoring), local guidance, and individual 
circumstances. The protocol did not specify uniform insulin titration algorithms. After the 
first dose of the study drug, the daily insulin dose was recommended to be reduced by 
up to 20% to balance the risk of hypoglycemia and DKA due to excessive insulin dose 
reduction (14, 18, 19), before subsequently attempting to titrate it back as far as 
possible to baseline levels. Events of potential DKA were monitored throughout the 
study. Patients were educated on identifying potential signs/symptoms of DKA and its 
management at each visit and were provided with combined glucose and ketone meters 
and instructions for use. Patients were required to record blood ketone test results and 
relevant risk factors and contact the study site if their self-measured blood ketone 
reading was ≥0.6 mmol/L, irrespective of glucose values to avoid missing any events of 
euglycemic DKA. CGM was done using the electronic CGM sensor, Dexcom G4 
platinum, over 2-week periods. Patients were trained to wear and operate the sensor as 
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required for the study according to the manufacturer’s instructions. Supplementary 
table 2 provides additional details about the study methodology.  
 
Outcomes   
The primary efficacy outcome was the change from baseline in HbA1c after 24 weeks of 
double-blinded treatment with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus 
placebo plus adjustable insulin. A sensitivity analysis for the primary efficacy endpoint 
was done for patients discontinuing treatment early. Secondary efficacy outcomes 
included evaluation of the following changes from baseline after 24 weeks of study 
treatment: percent change in total daily insulin dose (TDD); percent change in body 
weight; masked CGM endpoints including change in mean value of 24-hour glucose 
readings, change in mean amplitude of glucose excursion (MAGE; the arithmetic mean 
of the blood glucose increases or decreases when both ascending and descending 
segments exceeded the value of 1 SD of the blood glucose for the same 24 h period 
(20)), and change in the percent of 24-hour glucose readings within the target range of 
>70 mg/dL–≤180 mg/dL (>3.9–≤10.0 mmol/L) and finally, the proportion of patients 
achieving an HbA1c decrease of ≥0.5% without severe hypoglycemia. The proportion of 
patients achieving HbA1c reduction of ≥0.5% and those achieving HbA1c <7% after 24 
weeks of treatment were investigated as exploratory outcomes.     
Safety and tolerability were evaluated throughout the study by assessing AEs and 
serious AEs (SAEs), vital signs, physical examination findings, electrocardiogram and 
laboratory values and home BOHB readings. AEs of special interest included 
hypoglycemia, DKA, hepatobiliary AEs, genital infections, urinary tract infections, 
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volume depletion, fractures, worsening renal function, hypersensitivity, and 
cardiovascular AEs. Hypoglycemia was classified according to the American Diabetes 
Association (ADA) classification criteria (21) into severe hypoglycemia (requiring 
assistance of another person to raise glucose levels and promote neurological 
recovery), documented symptomatic hypoglycemia (featuring typical hypoglycemia 
symptoms and a plasma glucose concentration ≤70 mg/dL [≤3.9 mmol/L]), 
asymptomatic hypoglycemia (unaccompanied by typical hypoglycemia symptoms, but 
with plasma glucose of ≤70 mg/dL [≤3.9 mmol/L]), probable symptomatic hypoglycemia 
(typical hypoglycemia symptoms but without a plasma glucose determination), and 
pseudo/relative hypoglycemia (patient-reported hypoglycemia symptoms with plasma 
glucose >70 mg/dL [>3.9 mmol/L] but approaching that level). Analysis of hypoglycemia 
was based on capillary, patient-measured, SMBG values.   
Events of potential DKA were identified based on symptoms, diagnoses or home ketone 
values. Additionally, investigators were asked whether AEs satisfying a wide list of 
preferred terms (from MedDRA queries) could be potential DKA events. All such events 
were then adjudicated by an independent blinded DKA Adjudication Committee, and 
classified as definite, possible, or unlikely DKA. Definite DKA cases were confirmed by 
the presence of acidosis, diagnosis of low blood pH of <7.3, decreased serum 
bicarbonate levels (≤18 mEq/L), and symptoms/signs, as listed by the ADA consensus 
statement on diagnosis of DKA (22). The other two adjudication categories, “possible” 
and “unlikely” were not explicitly defined. Hyperglycemia was not included in the criteria 
in order to not miss any events of euglycemic DKA. 
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Sample size and power  
To detect a difference in mean HbA1c of 0.35% between each dapagliflozin treatment 
group and placebo at the two-sided 0.0262 significance level (based on Dunnett and 
Tamhane step-up procedure) (23), with a standard deviation (SD) of 1.1%, 243 patients 
were required in each treatment group to provide ~90% power. Assuming that 5% of 
patients would not have a post-baseline assessment, 768 patients (256 patients per 
treatment arm) were planned to be randomized to one of the three treatment groups in 
1:1:1 ratio. Among these 768 subjects, approximately 160 were planned to be enrolled 
in Japan. 
 
Statistical analysis 
Efficacy analyses were performed on the full analysis set, comprising all randomized 
patients receiving ≥1 dose of study medication during the short-term double-blind 
period, who had a baseline and any post-baseline assessment. Safety analyses were 
performed on the safety analysis set, comprising all randomized patients receiving ≥1 
dose of study medication. Treatment effects were determined through pair-wise 
comparisons between each dapagliflozin group and placebo.  
For an overall Type I error rate of 5% for the primary endpoint, a Dunnett and Tamhane 
step-up procedure (23) was used. This allowed for the correlation of 0.5 between the 
standard normal deviate for each comparison. Statistical significance would be declared 
for both doses at the two-sided 5% level if the two-sided p-values from both pairwise 
comparisons were smaller than 5%. If the larger p-value among the two pairwise 
comparisons was greater than 5% and the smaller p-value was below 2.62%, then 
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statistical significance would be declared for the latter comparison. Statistical analyses 
for secondary efficacy endpoints were only conducted if there was a statistically 
significant difference in the primary endpoint for both pairwise comparisons (i.e., 
dapagliflozin 5 mg versus placebo and dapagliflozin 10 mg versus placebo) using the 
Dunnett and Tamhane step-up procedure (23). The primary estimand for the primary 
endpoint was treatment difference at Week 24 if subjects did not discontinue 
randomized treatment. The primary analysis of the change in HbA1c from baseline to 
Week 24 was based on a longitudinal repeated measures analysis using direct 
likelihood.  The model included the fixed categorical effects of treatment, week, 
randomization stratification factor (one term for each combination of all stratification 
factors), and treatment-by-week interaction as well as the continuous fixed covariates of 
baseline measurement and baseline measurement-by-week interaction. 
For secondary endpoints, point estimates and 2-sided 95% confidence intervals (CI) for 
the mean change within each treatment group, and the difference in mean change 
between each dapagliflozin treatment group and placebo were calculated. The t-
statistics corresponding to the Type III sums of squares for the differences in the least 
squares means between each dapagliflozin group and placebo at Week 24 were 
calculated. For efficacy parameters measured during every visit (e.g., parameters from 
CGM or from 6-point SMBG), longitudinal repeated measures analyses using direct 
likelihood and the SAS procedure PROC MIXED was used. Relevant protocol 
deviations (those having the potential to impact the results of the primary analysis) were 
reviewed prior to the unblinding of the study.  
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The proportion of subjects achieving HbA1c reduction of ≥0.5%  at Week 24 and the 
proportion of patients achieving HbA1c of <7% at Week 24 was analyzed using logistic 
regression with adjustment for baseline HbA1c and stratum and using last observation 
carried forward. Odds ratios (ORs) and corresponding 95% CIs for each treatment 
group vs. placebo were presented for each of these endpoints. 
 
Results  
Patient disposition 
Between July 08, 2015 and September 02, 2017, 1465 patients were enrolled in the 
study, of which 815 were randomly assigned to either dapagliflozin 5 mg (n=271), 
dapagliflozin 10 mg (n=270) or placebo (n=272); two patients were randomized but not 
dosed (Figure 1). Overall, 728 patients (89.5%) completed the double-blind treatment 
period. The main reasons for study discontinuation were occurrence of AEs (4.8%), 
withdrawal of consent by the patient (1.7%), and patient request for treatment 
discontinuation (1.2%).    
 
Patients 
Baseline characteristics and demographics were balanced across treatment groups 
(Table 1). The mean age of the study population was 42.7 years with a mean time since 
diagnosis of type 1 diabetes of 19.3 years. The majority of the patients were White 
(78.4%); and overall, 34.6%, 33.5%, and 18.9% of the patients were from North 
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America, Europe, and Japan, respectively. The mean baseline HbA1c was 8.44%, 
mean baseline body weight was 79.2 kg, and mean baseline BMI was 27.6 kg/m2. The 
mean TDD at baseline was 57.81 IU (0.72 IU/kg), with 537 patients (66.1%) using MDI 
and 276 (33.9%) using CSII; 258 patients (31.7%) were using CGM at baseline.  
 
Efficacy  
At Week 24, there were significant reductions in HbA1c with both dapagliflozin doses 
versus placebo. Mean changes (95% CI) in HbA1c from baseline to Week 24 versus 
placebo were −0.37% (−0.49, −0.26; p<0.0001) and −0.42% (−0.53, −0.30; p<0.0001; 
Figure 2a) for dapagliflozin 5 mg and 10 mg, respectively. Initial reduction in HbA1c 
was observed in the first 4 weeks and the effect was maintained throughout the study. A 
sensitivity analysis showed that these results were not affected by missing data 
(Supplementary table 3). Other changes in HbA1c based on subgroup analyses (use 
of CGM and method of insulin administration) have been detailed in Supplementary 
tables 4 and 5.      
 
At Week 24, dapagliflozin had significant effects on all secondary endpoints. Mean 
percent change (95% CI) in TDD from baseline to Week 24 for dapagliflozin 5 mg and 
10 mg versus placebo was −10.78% (−13.73, −7.72; p<0.0001) and −11.08% (−14.04, 
−8.02; p<0.0001; Figure 2b), respectively. Reductions in TDD occurred in the first 2 
weeks of treatment, and were maintained thereafter throughout the study. At Week 24, 
adjusted mean changes (standard error [SE]) for basal insulin for dapagliflozin 5 mg, 10 
mg and placebo were −11.19% (1.5), −16.71% (1.4), and 1.46% (1.7), respectively; for 
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bolus insulin, these were −11.60% (2.0), −8.30% (2.1), and −2.59% (2.2), respectively. 
Compared with placebo, mean change (95% CI) in body weight from baseline to Week 
24 was −3.21% (−3.96, −2.45; p<0.0001) for dapagliflozin 5 mg, and −3.74% (−4.49, 
−2.99; p<0.0001) for 10 mg (Figure 2c). Reduction in body weight was consistent 
through the study, without plateauing at Week 24.  
At Week 24, a greater proportion of patients on dapagliflozin showed HbA1c reduction 
of ≥0.5% without severe hypoglycemia (dapagliflozin 5 mg: 105/266, 39.5%; 10 mg: 
111/267, 41.6%; placebo: 54/269, 20.1%). The OR (95% CI) versus placebo for 
achieving an HbA1c reduction of ≥0.5% without experiencing severe hypoglycemia 
were statistically significant for both dapagliflozin doses: 2.71 (1.81, 4.06) for 
dapagliflozin 5 mg versus placebo; 3.07 (2.05, 4.60) for dapagliflozin 10 mg versus 
placebo; p<0.0001 for both (Figure 2D). After 24 weeks of treatment, the proportion of 
patients achieving HbA1c reduction of ≥0.5% after 24 weeks of treatment was 42.9%, 
44.6%, 21.2% for dapagliflozin 5 mg, 10 mg and placebo, respectively (OR [95% CI] for  
dapagliflozin 5 mg versus placebo, 2.97 [1.99, 4.42]; OR [95% CI] for dapagliflozin 10 
mg versus placebo, 3.30 [2.22, 4.92]). Given that the lower bound of HbA1c at inclusion 
was 7.5% at baseline, a relatively small, the proportion of patients achieved an HbA1c 
of <7% after 24 weeks of treatment. The percentages were 4.9%, 3.7%, 1.5% for 
dapagliflozin 5 mg, 10 mg and placebo, respectively (OR [95% CI] for dapagliflozin 5 mg 
versus placebo, 3.55 [1.12, 11.18]; OR [95% CI] for dapagliflozin 10 mg versus placebo, 
2.45 [0.75, 8.03]).  
Based on the CGM data, the change in mean interstitial glucose, MAGE and time in the 
target glycemic range from baseline to Week 24 showed significant improvements for 
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both dapagliflozin doses versus placebo (Supplementary table 6). Mean change from 
baseline (95% CI) in 24-h CGM values at Week 24 versus placebo was –15.66 mg/dL 
(–20.26, –11.05; p<0.0001) and –19.74 mg/dL (–24.34, –15.14; p<0.0001) for 
dapagliflozin 5 mg and 10 mg, respectively. Mean change (95% CI) in MAGE at Week 
24 from baseline, versus placebo was –9.85 mg/dL (–14.66, –5.03; p<0.0001) for 
dapagliflozin 5 mg and –9.36 mg/dL (–14.16, –4.55; p=0.0001) for dapagliflozin 10 mg. 
Mean change from baseline (95% CI) versus placebo in the 24-h CGM values within the 
target glucose range (>70–≤180 mg/dL [>3.9–≤10.0 mmol/L]) at Week 24 was 9.02% 
(6.97, 11.06; p<0.0001) and 10.70% (8.66, 12.74; p<0.0001) for dapagliflozin 5 mg and 
10 mg, respectively. More than 50% of the CGM readings were in the target range at 
Week 24 for the dapagliflozin groups.    
 
Safety  
AEs were reported for 72.7%, 67.0%, and 63.2% of the patients receiving dapagliflozin 
5 mg, 10 mg and placebo, respectively, while SAEs were reported for 6.6%, 2.6% and 
1.8% of the patients (Table 2). The majority of AEs were of mild or moderate intensity. 
Discontinuations due to AEs occurred in 6.3%, 4.4%, and 4.0% of subjects in the 
dapagliflozin 5 mg, 10 mg, and placebo groups, respectively. There was one death 
during the screening period and none during the double-blind period. 
The most common AEs were viral upper respiratory tract infection (occurring in 39 
[14.4%], 44 [16.3%], and 42 [15.4%] patients in the dapagliflozin 5 mg, 10 mg, and 
placebo groups, respectively), upper respiratory tract infection (in 16 [5.9%], 12 [4.4%], 
and 12 [4.4%%] patients), headache (in 10 [3.7%], 15 [5.6%], 10 [3.7%] patients), and 
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pollakiuria (in 22 [8.1], 14 [5.2], and 6 [2.2%] patients). There were few cardiovascular 
(1, 3, and 2 in the dapagliflozin 5 mg, 10 mg, and placebo groups, respectively) or 
hepatic events (5, 5, and 6). Genital infections were more common in the dapagliflozin 
groups versus placebo, with a similar frequency in both dapagliflozin groups, and these 
occurred more commonly in females than in males (dapagliflozin 5 mg: 15.7% versus 
2.5%; dapagliflozin 10 mg: 12.8% versus 1.7%; placebo: 3.3% versus 0%). SAEs of 
genital infection were not reported in any treatment group. Occurrence of UTI was 
balanced across treatment groups, but was more common in females than in males 
(dapagliflozin 5 mg: 11.8% versus 0%; dapagliflozin 10 mg: 6.0% versus 0.8%; placebo: 
7.2% versus 0.8%).  
Overall, a similar proportion of subjects in each treatment group experienced 
hypoglycemia and severe hypoglycemia (hypoglycemia: 82.3%, 85.6%, and 86.0 % of 
patients receiving dapagliflozin 5 mg, 10 mg, and placebo, respectively; severe 
hypoglycemia: 6.3%, 8.5%, and 7.7%). Occurrence of different types of hypoglycemia 
based on ADA classification is shown in Supplementary table 7. Two (0.7%) patients 
receiving dapagliflozin 5 mg discontinued medication due to an SAE of hypoglycemia.  
DKA events adjudicated as definite, possible, or unlikely are shown in Table 4; only 
definite events had findings consistent with the ADA definition (22), but without the 
requirement for hyperglycemia, as outlined in the adjudication charter. Thirteen definite 
DKA events were observed [7 (2.6%), 6 (2.2%), and 0 patients receiving dapagliflozin 5 
mg, 10 mg and placebo, respectively]. Of these, 10 were SAEs, with 6 and 4 events in 
the dapagliflozin 5 and 10 mg groups, respectively. All but three events in three patients 
were documented as receiving conventional DKA treatment including administration of 
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intravenous (IV) fluids and insulin. Of the three aforementioned patients, two received 
only IV fluids as treatment for DKA while one patient did not have treatment recorded. 
Insulin pump failure and missed insulin dose were the most common primary causes of 
definite DKA. Events identified as possible or unlikely did not fulfill the ADA criteria. 
Conventional DKA treatment with IV fluids and insulin was only documented for two of 
the possible events. Two of the possible DKA events (both in the dapagliflozin 5 mg 
group) and none of the unlikely events were reported as SAEs. Euglycemic DKA, 
defined as plasma glucose <250 mg/dL on the home meter when highest BOBH levels 
are observed, occurred in two events of definite DKA in those receiving dapagliflozin 5 
mg and in one event in a subject receiving dapagliflozin 10 mg. Data on concurrent 
glucose and beta-hydroxybutyrate were not available for six events. Details about self-
monitored blood ketone measurements and a listing of maximum ketone values for 
patients with definite DKA events are provided in Supplementary tables 8 and 9.  
 
Conclusions  
DEPICT-2 is the second of two randomized, double-blind, phase 3 studies evaluating 
the efficacy and safety of dapagliflozin as adjunct therapy to adjustable insulin in adult 
patients with inadequately controlled type 1 diabetes. The study design is the same as 
that of the 24-week DEPICT-1 study; however, there are some differences between the 
studies, such as fewer site visits in the DEPICT-2 study, and the geographical footprint 
of DEPICT-2, which included patients from North America, Latin America, Europe, and 
Japan (with 19.7% Asian and 18.9% Japanese patients). In contrast, the DEPICT-1 
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study predominantly had European (59.3%) and North American (27.0%) populations, 
with only 3.6% patients from the Asia-Pacific region (Australia). 
 
Consistent with the DEPICT-1 results, in the current study, dapagliflozin significantly 
improved glycemic control, mean glucose levels, glycemic variability, and time in 
glycemic target range, and decreased body weight and TDD. Treatment was well 
tolerated, with no increase in hypoglycemia compared with placebo. This strengthens 
the weight of evidence that dapagliflozin could play an important role in the 
management of type 1 diabetes, helping to address several important unmet treatment 
needs, including improved glycemic control with decreased glycemic variability, weight 
loss and decrease in insulin dose.  
The results seen with dapagliflozin in the DEPICT studies are broadly aligned to those 
seen in the phase 3 inTandem3 study, which examined the effects of sotagliflozin, a 
non-selective SGLT2/SGLT1 inhibitor, added to insulin treatment in patients with type 1 
diabetes (17). Direct comparisons between the DEPICT studies and InTandem 3 are 
difficult as definitions around safety events could potentially differ. Further, InTandem 3 
had particular instructions for insulin adjustment whereas in the DEPICT studies, insulin 
dose was adjusted as deemed appropriate by the investigator, local guidance and 
individual circumstances. No results are yet reported from ongoing phase 3 studies of 
other selective SGLT2 inhibitors in type 1 diabetes, such as the empagliflozin EASE 
studies (24, 25).  
Benefits of using SGLT2 inhibitors in the treatment of type 1 diabetes should be 
balanced against the increased risk of DKA. The incidence of definite DKA events in 
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DEPICT-2 was higher compared with DEPICT-1 (dapagliflozin 5 mg versus 
dapagliflozin 10 mg versus placebo: 5.83, 4.99, and 0 per 100 patient-years in DEPICT-
2, respectively; 3.29, 3.78, and 2.64 per 100 patient-years in DEPICT-1). This difference 
between the studies does not appear to be related to the study conduct or geography, 
since the studies were very similar and the events tended to occur in the same regions 
in both studies. We postulate that chance variability due to the small number of events 
is a more likely explanation for the inter-study differences. Further, the risk factors for 
developing DKA in DEPICT-2 was generally consistent with that seen in other studies of 
SGLT2 inhibitors in the treatment of type 1 diabetes (17, 19, 26), with events often 
associated with missed insulin doses or insulin pump failure. The imbalance in DKA 
events seen in the dapagliflozin versus placebo groups in DEPICT-2, despite receiving 
the same education and monitoring instructions as in DEPICT-1, suggests that, if 
approved for the indication, the DKA risk should be carefully considered if using 
dapagliflozin for the treatment of type 1 diabetes in the real world. It must be noted that 
when they did occur, events of DKA were resolved using conventional treatment. The 
increased risk of DKA when using dapagliflozin in type 1 treatment may be partly 
mitigated by educating patients about the risk factors for DKA and by ensuring that they 
are able to monitor blood glucose regularly as well as ketones. Avoiding excessive 
insulin dose reductions (>20% reduction) on initiation of adjunct dapagliflozin therapy 
(14, 16, 18, 19) and subsequent caution in insulin dose reduction during treatment may 
be important to mitigate against the increased DKA risk. Any insulin dose reduction 
should be based on the physician’s judgment and individual patient requirements. Since 
the risk of DKA seems to be elevated in those with T1DM on SGLT (2 or 1/2) inhibitors, 
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extra caution should be exercised when factors that predispose to DKA occur such as 
infections or sick days that may also require interruption of dosing of the SGLT 
inhibitors. 
There are some limitations to this study. Firstly, the current 24-week results only provide 
evidence of relatively short-term data regarding therapeutic benefit and risks; this will be 
addressed in the ongoing 28-week extension phase for this study and the preceding 
DEPICT-1 study.  Secondly, exclusion of DKA- and hypoglycemia-prone patients and 
strict monitoring of DKA and hypoglycemia in this trial setting differ from the real-world 
situation. Finally, the decision not to include a protocol-mandated insulin titration 
algorithm, chosen to more closely reflect clinical practice and the real-world setting, 
could potentially mask the full glycemic potential of dapagliflozin.   
In summary, these results demonstrate that in patients with type 1 diabetes 
inadequately controlled on insulin, adjunct dapagliflozin (5 and 10 mg) therapy 
significantly improves HbA1c, mean glucose levels, glycemic variability, time in glycemic 
target range and reduces body weight and TDD. Overall, the treatment was well 
tolerated, with no increase in hypoglycemia versus placebo although there were more 
events of DKA in patients receiving dapagliflozin in this study. Taken together, the 
DEPICT studies provide robust short-term evidence for dapagliflozin as a suitable 
candidate for use as adjunct therapy to adjustable insulin to improve glycemic control in 
patients with type 1 diabetes. 
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Table 1: Demographic and baseline characteristics 
Characteristic Dapagliflozin 5 
mg + Insulin 
(n=271) 
Dapagliflozin 10 
mg + Insulin 
(n=270) 
Placebo + 
Insulin 
(n=272) 
Gender 
     Male 118 (43.5%) 121 (44.8%) 119 (43.8%) 
Female  153 (56.5%) 149 (55.2%) 153 (56.3%) 
Age, years  42.7 (13.35) 42.4 (12.80) 43.0 (13.73) 
Body weight, kg  78.74 (17.38) 80.06 (18.30) 78.88 (18.87) 
BMI, kg/m2  27.27 (5.13) 27.80 (5.53) 27.62 (5.41) 
Race 
White  210 (77.5%) 219 (81.1%) 208 (76.5%) 
Black or African-American  4 (1.5%) 7 (2.6%) 1 (0.4%) 
Asian  57 (21.0%) 44 (16.3%) 59 (21.7%) 
Other  0 0 4 ( 1.5) 
Geographic region 
North America  96 (35.4%) 96 (35.6%) 89 (32.7%) 
Latin America  41 (15.1%) 32 (11.9%) 33 (12.1%) 
Europe  79 (29.2%) 101 (37.4%) 92 (33.8%) 
Asia-Pacific  55 (20.3%) 41 (15.2%) 58 (21.3%) 
Duration of T1D, years   19.35 (11.79) 19.45 (11.90) 18.98 (11.65) 
Total baseline insulin dose 
     Dose, IU 58.19 (27.93) 58.68 (28.26) 56.57 (25.23) 
     Dose/weight, IU/kg 0.73 (0.26) 0.72 (0.27) 0.71 (0.24) 
Method of insulin administration 
     MDI 179 (66.1%) 178 (65.9%) 180 (66.2%) 
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     CSII 92 (33.9%) 92 (34.1%) 92 (33.8%) 
Use of CGM (Yes) 88 (32.5%) 85 (31.5%) 85 (31.3%) 
HbA1c (%) 8.45 (0.69) 8.43 (0.69) 8.43 (0.65) 
HbA1c (mmol/mol) 69 (7.5) 69 (7.5) 69 (7.1) 
HbA1c at randomization    
     ≥7.5% and <9.0% 211 (77.9%) 210 (77.8%) 211 (77.6%) 
     ≥9.0% and ≤10.5% 60 (22.1%) 60 (22.2%) 61 (22.4%) 
Data are n (%) or mean (SD).  
BMI, body mass index; CGM, continuous glucose monitoring; CSII, continuous 
subcutaneous insulin infusion; HbA1c, glycated hemoglobin; MDI, multiple daily 
injections; T1D, type 1 diabetes; SD, standard deviation.  
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Table 2: Safety summary  
Characteristic Dapagliflozin 
5 mg + 
Insulin 
(n=271) 
Dapagliflozin 
10 mg + 
Insulin 
(n=270) 
Placebo + 
Insulin 
(n=272) 
Adverse events     
≥1 AEs 197 (72.7%) 181 (67.0%) 172 (63.2%) 
≥1 AEs related to the study drug 78 (28.8%) 71 (26.3%) 32 (11.8%) 
AE leading to study discontinuation  17 (6.3%) 12 (4.4%) 11 (4.0%) 
AEs of special interest 
Genital infection  27 (10.0%) 21 (7.8%) 5 (1.8%) 
Urinary tract infection  18 (6.6%) 10 (3.7%) 12 (4.4%) 
Renal impairment/failure 2 (0.7%) 0 0 
Fractures 4 (1.5%) 3 (1.1%) 2 (0.7%) 
Hypotension/Dehydration/Hypovolemia 8 (3.0%) 2 (0.7%) 2 (0.7%) 
Hypersensitivity 18 (6.6%) 10 (3.7%) 17 (6.3) 
Cardiovascular events 1 (0.4%) 3 (1.1%) 2 (0.7%) 
Serious adverse events  
≥1 SAEs 18 (6.6%) 7 (2.6%) 5 (1.8%) 
≥1 SAEs related to the study drug 13 (4.8%) 3 (1.1%) 2 (0.7%) 
SAEs leading to study discontinuation  12 (4.4%) 3 (1.1%) 3 (1.1%) 
Death 0 0 0 
Hypoglycemia  
32 
 
≥1 SAE of hypoglycemia 5 (1.8%) 0 1 (0.4%) 
Hypoglycemia leading to study 
discontinuation  
2 (0.7%) 0 0 
Ketone-related events    
≥1 ketone related SAEs   9 (3.3%) 3 (1.1%) 0 
Ketone-related SAE leading to study 
discontinuation  
8 (3.0%) 2 (0.7%) 0 
Adjudicated definite DKA 
Number of patients with definite DKA 7 (2.6%) 6 (2.2%) 0 
Number of events adjudicated as definite 
DKA  
7 (25.0%) 6 (33.3%) 0 
Incidence rate per 100 patient-years 5.83 4.99 0 
Number of CSII users experiencing definite 
DKA   
6 (6.5%) 3 (3.3%) 0 
Male: female ratio in patients experiencing 
definite DKA  
   
Severity of adjudicated DKA events 
Mild  3 (42.9%) 3 (50.0%) NA 
Moderate   3 (42.9%) 1 (16.7%) NA 
Severe  1 (14.3%) 2 (33.3%) NA 
Primary cause for adjudicated definite DKA events 
Insulin pump failure 1 (14.3%) 2 (33.3%) 0 
Missed insulin dose 2 (28.6%) 1 (16.7%) 0 
Not identified 4 (57.1%) 0 0 
Other 0 3 (50.0%)* 0 
Mean percent insulin total daily dose (IU) 
reduction compared with baseline for week 
before DKA event†  
–16.83 –21.97 NA 
Mean percent insulin total daily dose (IU) –15.68 –22.93 NA 
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reduction compared with baseline at  the 
end of 24 week treatment period†  
Events adjudicated as not DKA  
Number of patients with event(s) 
adjudicated as possible DKA 
6 (2.2%) 4 (1.5%) 2 (0.7%) 
Number of events adjudicated as 
possible DKA  
7 (25.0%) 4 (22.2%) 2 (13.3%) 
Number of patients with event(s) 
adjudicated as unlikely DKA 
8 (3.0%) 4 (1.5%) 7 (2.6%) 
Number of events adjudicated as 
unlikely DKA  
14 (50.0%) 8 (44.4%) 13 (86.7%) 
All data are n (%). Table includes non-SAEs with onset on or after the first date/time of 
double-blind treatment and on or prior to the last day of short-term double-blind 
treatment plus 4 days or up to the start date of the long-term period if earlier. Table 
Includes SAEs with onset on or after the first date/time of double-blind treatment and on 
or prior to the last day of short-term double-blind treatment plus 30 days or up to the 
start date of the long-term period if earlier. Only hypoglycemia and DKA reported by the 
investigator as SAE are included in the AE, related AE, SAE, related SAE, and AE 
leading to discontinuation summary lines. All reported hypoglycemia events and events 
sent for DKA adjudication with onset within 4 days of last day of treatment are included 
in the hypoglycemia and events sent for DKA adjudication lines respectively.  
*Cause for DKA included alcohol intake, stress and stroke.  
†Means apply for patients with definite DKA.  
AE, adverse event; CSII, continuous subcutaneous insulin infusion; DKA, diabetic 
ketoacidosis; NA, not applicable; SAE, serious adverse event. 
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Figure legends 
Figure 1: Patient disposition.    
 
Figure 2: Change in (A) HbA1c (%), (B) total daily dose of insulin (%), and (C) total 
body weight (kg) over 24 weeks and (D) proportion of patients achieving an 
HbA1c reduction of ≥0.5% without severe hypoglycemia (%) at Week 24*     
*Patients per time point indicate the number of patients with data at that time point as 
defined by the visit windows in the protocol regardless of whether that patient was still 
receiving randomized treatment. 
BL, baseline; CI, confidence interval; DAPA, dapagliflozin; HbA1c, glycated hemoglobin; 
PBO, placebo; INS, insulin; SD, standard deviation; SE, standard error 
 
